Related news from
Mon, 08 Apr 2024 12:00:00 +0000	CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across ma
Wed, 03 Apr 2024 12:00:00 +0000	CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milest
Thu, 21 Mar 2024 12:00:00 +0000	CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors. “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “With his ext
Mon, 18 Mar 2024 12:00:00 +0000	CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of condi
Wed, 13 Mar 2024 10:28:28 +0000	CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags CytomX Therapeutics ( NASDAQ:CTMX ) Full Year 2023 Results Key Financial Results Revenue: US$101.2m (up 90% from FY...
Tue, 12 Mar 2024 12:30:00 +0000	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript March 11, 2024 CytomX Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial […]
Tue, 12 Mar 2024 10:46:50 +0000	Q4 2023 CytomX Therapeutics Inc Earnings Call Q4 2023 CytomX Therapeutics Inc Earnings Call
Mon, 11 Mar 2024 21:34:02 +0000	CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update Key Financial Highlights and Upcoming Clinical Milestones
Mon, 11 Mar 2024 21:20:03 +0000	CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mon, 11 Mar 2024 20:10:00 +0000	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 - - Management to hold conference call today at 5 p.m. EDT
Mon, 04 Mar 2024 13:00:00 +0000	CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events an
Tue, 27 Feb 2024 16:52:00 +0000	CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
Tue, 27 Feb 2024 13:00:00 +0000	CytomX Therapeutics to Present at Upcoming March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in March. TD Cowen’s 44th Annual Health Care Conference Date: Tuesday, March 5, 2024 Formal Presentation: 2:50 p.m. ET Location: Boston, MA Barclays 26th Annual Global Healthcare ConferenceDate: Thursday, March 14, 2024Fireside Chat: 11:
Tue, 13 Feb 2024 10:44:55 +0000	CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29% Key Insights Significant control over CytomX Therapeutics by retail investors implies that the general public has more...
Wed, 24 Jan 2024 17:14:00 +0000	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Wed, 24 Jan 2024 16:25:00 +0000	Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
Wed, 24 Jan 2024 13:00:00 +0000	CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b - Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it has received c
Tue, 23 Jan 2024 18:23:00 +0000	Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
Tue, 23 Jan 2024 17:12:00 +0000	Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.
Tue, 23 Jan 2024 16:44:00 +0000	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.